Celldex Says Expands Phase 2 ReACT Study In Recurrent Glioblastoma

(RTTNews) - Celldex Therapeutics, Inc. (CLDX), Monday announced expansion of the Phase 2 ReACT Study in Recurrent Glioblastoma. ReACT is a Phase 2 study designed to determine if adding rindopepimut to the standard of care for recurrent glioblastoma, Avastin, improves the outcomes for patients with recurrent EGFRvIII-positive glioblastoma. Based on early evidence of anti-tumor activity, including stable disease, tumor shrinkage and investigator-reported response, the company said it has begun expansion cohort of about 75 patients to better characterize the potential activity of rindopepimut in this refractory patient population.

Study endpoints include 6 month progression free survival rate, objective response rate, overall survival and safety and tolerability.